Review



ezh2 inhibitor gambogenic acid  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    MedChemExpress ezh2 inhibitor gambogenic acid
    Immunohistochemistry (IHC) data of AURKA and <t>EZH2</t> from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.
    Ezh2 Inhibitor Gambogenic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ezh2 inhibitor gambogenic acid/product/MedChemExpress
    Average 91 stars, based on 2 article reviews
    ezh2 inhibitor gambogenic acid - by Bioz Stars, 2026-02
    91/100 stars

    Images

    1) Product Images from "Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells"

    Article Title: Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

    Journal: Frontiers in Cell and Developmental Biology

    doi: 10.3389/fcell.2021.734287

    Immunohistochemistry (IHC) data of AURKA and EZH2 from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.
    Figure Legend Snippet: Immunohistochemistry (IHC) data of AURKA and EZH2 from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.

    Techniques Used: Immunohistochemistry, Expressing

    Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. ( E-F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA-LIHC based on TP3 mutation status.
    Figure Legend Snippet: Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. ( E-F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA-LIHC based on TP3 mutation status.

    Techniques Used: Migration, Staining, IF-P, Expressing, Mutagenesis



    Similar Products

    ezh2 inhibitor gambogenic acid  (MedChemExpress)
    91
    MedChemExpress ezh2 inhibitor gambogenic acid
    Immunohistochemistry (IHC) data of AURKA and <t>EZH2</t> from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.
    Ezh2 Inhibitor Gambogenic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ezh2 inhibitor gambogenic acid/product/MedChemExpress
    Average 91 stars, based on 1 article reviews
    ezh2 inhibitor gambogenic acid - by Bioz Stars, 2026-02
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunohistochemistry (IHC) data of AURKA and EZH2 from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

    doi: 10.3389/fcell.2021.734287

    Figure Lengend Snippet: Immunohistochemistry (IHC) data of AURKA and EZH2 from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.

    Article Snippet: The EZH2 inhibitor gambogenic acid was purchased from MCE (Shanghai, China).

    Techniques: Immunohistochemistry, Expressing

    Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. ( E-F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA-LIHC based on TP3 mutation status.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

    doi: 10.3389/fcell.2021.734287

    Figure Lengend Snippet: Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. ( E-F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA-LIHC based on TP3 mutation status.

    Article Snippet: The EZH2 inhibitor gambogenic acid was purchased from MCE (Shanghai, China).

    Techniques: Migration, Staining, IF-P, Expressing, Mutagenesis